DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 110 filers reported holding DENALI THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.27 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $22,703 | -42.1% | 450 | -10.0% | 0.00% | -50.0% |
| Q2 2021 | $39,220 | +37.4% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $28,550 | -31.8% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $41,880 | +133.8% | 500 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $17,915 | +48.2% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $12,090 | +38.1% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $8,755 | +0.5% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $8,710 | +13.7% | 500 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $7,660 | -48.4% | 500 | -30.1% | 0.00% | 0.0% |
| Q2 2019 | $14,843 | -10.6% | 715 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $16,602 | +703.6% | 715 | +615.0% | 0.00% | – |
| Q4 2018 | $2,066 | -5.0% | 100 | 0.0% | 0.00% | – |
| Q3 2018 | $2,174 | +42.6% | 100 | 0.0% | 0.00% | – |
| Q2 2018 | $1,525 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |